particip confer call regist use link button
receiv dial-in detail includ uniqu pin
add call calendar
netroadshow conferenc servic provid call pleas look email
verifi email address one-tim registr confirm
host
pravin dugel md partner retin consult arizona ltd
clinic professor usc roski institut keck school medicin univers
pleas see addendum report import disclosur
ew signific tavr share gain appear sustain check
crt believ sapien achiev low-to share
highli diverg bear competit share loss scenario
tavr setup appear favor potenti coronaviru impact ou tavr
unit unquantifi
link full note
post anoth strong quarterli revenu beat driven robust us momentum
revenu guidanc expect howev believ guidanc
conserv posit beat rais cours long-
term outlook remain compel hour weak appear overdon
reiter outperform price target
link full note
lower beovu sale estim substanti wake news rare seriou
report medic meet recent despit subsequ nv ep cut
reiter outperform rate nv growth still appear industri averag
new product line-up moder diminish
link full note
strong guid mahalo mr block vlociti join ohana
report strong w/ crpo sub book growth well
estimate crpo guid prior estimate revenue rais
keith block step co-ceo remain advisor marc
benioff expect littl disrupt risk vlociti deal make sens think
acceler vertic strategi reiter outperform pt
link full note
adama confirm pre-announce gocovri revenu reach
cautious optimist modestli improv patient retent metric signal
earli inflect new manag alreadi make encourag progress
gener settlement agreement anoth posit continu improv
could becom construct
link full note
aercap ytd mostli due concern regard coronaviru
compani scale expertis balanc sheet navig challeng near-
term environ fact expect aercap capit current environ
repurchas share acquir asset struggl airlin long-term
expect shift new asset provid new opportun grow
link full note
report attempt provid overview variou life scienc tool
segment detail segment competit dynam background associ
technolog expect growth segment area focu includ
cytometri mass spec/chromatographi electron microscopi nmr
link full note
wors expect driven tmus/ slowdown set
faster growth india guidanc better-than-fear could end
prove conserv posit lt outlook intact investor look
yield/defens expect continu outperform
link full note
convey takeaway investor day note import
ceo plant decis stay comp incent align well
link full note
vega momentum region resili set transform
think deal-clos nearli hand lift target price per share
appli multipl pro forma ebitda mil
base believ set grow double-digit next year eldorado
leadership result support opinion broad base out-performance
across region categori reiter outperform
link full note
report mix result revenue beat adj ep miss revenue guidanc
larg in-line although adj op inc adj ep miss expect management appear
make progress toward rightsiz busi commentari suggest
execut although remain sidelin look concret sign
progress also encourag improv retent
link full note
neg dk earn miss consensu refin lower forecast
el dorado result weakest vs estim in-lin net debt
lower forecast believ capital-expenditure number in-lin
expect dk secur project financ rais dividend
guid buyback maintain market perform pt
link full note
provid outlook in-lin consensu revenu adj
ep reflect lower adj ebitda margin increas oper depreci see
upsid adj ep guidanc accret capit alloc action
link full note
adj ebitda lighter expect top-lin growth better
consensu driven strong growth core servic busi ky medicaid
contract award expect spring biggest near-term catalyst
share price target declin reflect slower adj ebitda growth
think risk/reward attract level reit outperform
link full note
neg preannoun coronavirus-rel suppli chain shortag
wake extr press releas announc expect lower revenu
ep due coronaviru reduc oper forecast
expect suppli chain compon shortag result coronaviru neg
impact revenue/ep indic shortag may last beyond
potenti impact well reiter market perform
link full note
exposur rate volatil reduc unclear upsid downstream growth
lock larg portion lng carrier rate result less
earn volatil aim ship expos spot rate move forward
focus expand power downstream lng busi involv rel
smaller project sever potenti project hesit price
maintain outperform pt
link full note
gw report epidiolex revenue consist pre-announce gw
provid reason optim epidiolex grow includ expans
approv expect gw guidanc op ex somewhat
higher anticip adjust est consist decreas
dcf-base remain outperform
link full note
new confirm case outsid china tick tuesday driven korea
new case italy-rel iran-rel like much larger
undetect us cdc said question us see local
outbreak china case almost entir hubei report airlin
link full note
report arikayc sale reflect continu growth
us arikayc launch r/r ntm sale guidanc reflect
conserv view continu uptak track eu launch nrx
reauthor trend suggest continu growth though momentum appear
slow management plan trial
link full note
ocaliva sale laser focu nash launch upcom adcomm
ocaliva sale beat consensu line
estim sale y/i growth investor focu
remain upcom nash adcomm launch prep think adcomm
topic mainli focu potenti biopsi requir meaning phase
efficaci safeti on-going payor talk may pivot oca final label
link full note
iovanc report earn provid updat across pipelin bla
submiss lifileucel melanoma cervic track
end cash invest remain well financ
complet registration-en studi melanoma cervic cancer bla file
program
link full note
street clearli impress smaller earlier stage transact sinc
provid immedi clariti make potenti massiv
hole xyrem low-sodium strategi meaning protect
franchis still rev understand frustrat ebitda
believ valuat reflect skeptic
link full note
solid quarterli financi remain track tipifarnib hras-mut
hnscc registration-direct trial expect fulli enrol lymphoma
registration-direct trial begin new news includ partial clinic hold
early-stag asset erk inhibitor look address plan
expans cohort hnscc/escc outperform
link full note
bla accept margetuximab pipelin prioriti outlin
report financi updat prioriti expect
compani focus approv margetuximab expect pdufa
lower-risk asset includ margetuximab expans gastric/gej mahogani
registr trial flotetuzumab end cash
equival fund
link full note
shore foundat encourag path stabil
profit way cost save program focu top store best
mall increas custom lifetim valu loyalti digit backstag
privat label comp improv trend driven better
gift lead-up christma
link full note
quick take pluse minus lumpi expect set
worst kept secret hold true guid optic deliv oil higher
capital-expenditure critic lumpi year past capital-expenditure volum
leav oil capital-expenditure street potenti support strong
pr state higher growth signific multipl compress alongsid
narrow outspend key tenent bull case
link full note
major value-cr catalyst approach nexobrid escharex
report brought major surpris mdwd face major catalyst year
nexobrid escharex nexobrid near midyear bla file de-risk
clinic data partnership meanwhil escharex trial track
late interim analysi may show hint product efficaci vs santyl
present annual sale monopoli
link full note
mrtx financi reflect time execut expand clinic program
includ advanc kra inhibitor fda agreed-upon
monotherapi pivot ph singl arm trial nsclc combin work
pembrolizumab nsclc cetuximab provid new opportun
may support differenti profil competitor maintain outperform
link full note
quick take beat cost play defens
report telegraph jan op updat though
ebitdax better consensu lower help well exit
growth guidanc maintain lower capital-expenditure prior guid though guid
est total guid estimate expect
posit
link full note
cautious posit beat street high earn estim hawaii refin
margin stronger forecast flow impact work
capit net debt stabl liquid improv refin capac
tie asian margin equiti price action could therefor dictat
manag discuss exposur maintain market perform pt
link full note
summar highlight week end februari total market
w/w
link full note
usitc issu neg determin fab structur steel case
afternoon usitc issu neg final determin fabric
structur steel trade case remov effect ad cvd rate view neutral
neg fabric structur steel suppli associ upstream steel
consumpt view rs largest potenti beneficiari
link full note
expect supernu result continu reflect natur age process
trokendi oxtellar slow growth disclosur second
